Mirae Asset Global Investments Co. Ltd. decreased its stake in InterCure Ltd. (NASDAQ:INCR – Get Rating) by 78.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 182,459 shares of the company's stock after selling 654,427 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.43% of InterCure worth $1,295,000 at the end of the most recent reporting period.

Separately, Davy Global Fund Management Ltd bought a new position in InterCure in the first quarter worth $152,000. Hedge funds and other institutional investors own 9.34% of the company's stock.

InterCure Stock Down 1.3 %

Shares of INCR stock opened at $5.30 on Friday. The stock has a market cap of $226.50 million and a P/E ratio of 29.44. InterCure Ltd. has a one year low of $5.18 and a one year high of $8.77. The stock has a fifty day moving average price of $5.93 and a 200 day moving average price of $6.33. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.87 and a quick ratio of 1.26.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector.

See Also

• Get a free copy of the StockNews.com research report on InterCure (INCR)
• Why This Dip in Advanced Auto Parts May be an Opportunity
• MarketBeat: Week in Review 8/22 – 8/26
• Institutional Buying Put A Bottom In Marvell Technology
• Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
• 3 Reasons Dollar General's Rally Has Legs

Want to see what other hedge funds are holding INCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InterCure Ltd. (NASDAQ:INCR – Get Rating).

Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.